Biogen heads into Q4 earnings with MS drug pressure, while Leqembi and Skyclarys' growth could help offset declines ahead of its Feb. 6 report.

Biogen’s litifilimab has received Breakthrough Therapy Designation from the US FDA to treat cutaneous lupus erythematosus ...

If you are wondering whether Biogen's current share price gives you good value for the risk you are taking, you are not alone. Over the last year the stock returned 25.0%. The 3 year and 5 year ...

Biogen BIIB announced that the FDA has granted the Breakthrough Therapy designation to its investigational, first-in-class, ...

The Phase III AMETHYST study is currently assessing litifilimab’s safety and efficacy, with results anticipated in 2027.

AI-generated summary reviewed by our newsroom. Read our AI Policy. Biogen plans to beef up its Research Triangle Park operations with $2 billion in new local spending, the company announced Monday.

Proposed acquisition represents meaningful step forward in Biogen’s strategy for sustainable growth, adding a highly complementary innovative product in an area of high unmet medical need Expected to ...

– Investigational salanersen (ION306/BIIB115) developed using novel Ionis antisense chemistry with the potential to achieve high efficacy and once-yearly dosing – – Interim Phase 1 data show children ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Discover the strategic reasons ...

(The Center Square) – Modernization of “manufacturing technologies and controls through further advanced automation and artificial intelligence” are helping trigger Biogen’s commitment of $2 billion ...